Glucosa Altan

Glucosa Altan is an intravenous solution that contains glucose, anhydrous as its sole active ingredient. The product is supplied in a sterile liquid form, with strength not specified, and is marketed in the European Union. It is classified as an excipient used to provide a source of carbohydrate and fluid during intravenous therapy. Glucosa Altan is intended for use under professional medical supervision in clinical settings.

Glucosa Altan is employed in clinical practice primarily as an intravenous carbohydrate source and fluid supplement. It is indicated for a range of therapeutic situations where rapid glucose delivery is required.

- Provide an immediate source of glucose for patients unable to eat orally. - Maintain blood sugar levels during perioperative or critical‑care situations. - Serve as a diluent for compatible intravenous medications. - Support fluid balance when combined with electrolytes. - Used in pediatric and adult settings under physician direction.

Side effects associated with Glucosa Altan are generally related to the intravenous administration of a glucose solution. Both common and rare reactions have been reported in clinical use.

Common: - Transient hyperglycemia that resolves without intervention. - Mild irritation or pain at the infusion site. - Temporary increase in urine output due to osmotic diuresis. - Slight elevation of serum sodium when mixed with saline.

Serious: - Severe hyperglycemia leading to metabolic acidosis. - Allergic reaction presenting as rash, itching, or hives. - Fluid overload causing pulmonary edema in susceptible patients. - Electrolyte imbalance, particularly hyponatremia, with large-volume infusions.

When using Glucosa Altan, healthcare professionals should observe several precautionary measures to ensure patient safety and optimal therapeutic outcomes.

- Verify patient’s blood glucose level before initiating the infusion. - Adjust infusion rate in patients with diabetes or impaired glucose tolerance. - Monitor for signs of fluid overload, especially in cardiac or renal disease. - Use aseptic technique to prevent catheter‑related infections. - Avoid rapid administration in neonates and infants. - Document total volume and concentration administered in the medical record.

Glucosa Altan may interact with other intravenous agents or medications that affect glucose metabolism, fluid balance, or electrolyte status. Awareness of these interactions helps prevent adverse events.

Avoid: - Co‑administration with high‑dose insulin without close glucose monitoring. - Simultaneous infusion of hypertonic dextrose solutions exceeding recommended osmolarity. - Use with medications that cause severe hypoglycemia, such as sulfonylureas, without adjustment.

Use with caution: - Concurrent IV fluids containing electrolytes; monitor serum sodium and potassium. - Patients receiving total parenteral nutrition; adjust carbohydrate contribution accordingly. - Individuals with renal impairment; assess fluid volume and glucose clearance.